Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer
In summary, the glycolysis-associated gene signature established by us exhibited a high predictive performance for the prognosis, immunotherapeutic responsiveness, and chemotherapeutic sensitivity of BCa. And, The model also might function as a chemotherapy and immune checkpoint inhibitor (ICI) treatment guidance.
Authors
- Shaobo Yang (ORCID: https://orcid.org/0009-0001-1255-8445)
- Zhouliang Wu
- Xiaoliang Zhou (ORCID: https://orcid.org/0000-0002-5430-1306)
- Hailong Hu (ORCID: https://orcid.org/0000-0002-0565-7752)
- Wei Su (ORCID: https://orcid.org/0000-0001-6818-0149)
- Jian Guo (ORCID: https://orcid.org/0000-0002-8730-6816)
- Zhe Zhang (ORCID: https://orcid.org/0000-0002-7488-078X)
- Chong Shen (ORCID: https://orcid.org/0000-0002-4566-1115)
- Yong Suo
- Zhenqian Fan
Institutions
- Chinese People's Armed Police General Hospital (CN)
- Second Hospital of Tianjin Medical University (CN)
- Affiliated Hospital of Hebei University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1430583
- Citations
- 6
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.04